The early results in treating affective disorder with the NK1R antagonist aprepitant were promising, but no effect was found in a controlled treatment trial of depression [Hafizi et al., 2007; McCabe et al., 2009; Chandra et al., 2010]. Here, TACR1 is linked to depressive symptom measurement.